SUBSCRIBE
SUBSCRIBE
News   Drug Development

XOMA (US) LLC Unveils Strategy, Provides Update On NEUPREX(R); European Effort Advances Toward Orphan Drug Designation And Approval Under Exceptional Circumstances; US Trials Progress

August 15, 2006 | 
1 min read

XOMA Ltd. (Nasdaq:XOMA) today unveiled its strategy and provided an update on the status of its efforts to advance NEUPREX(R) (opebacan) toward regulatory approval in Europe and the US in multiple disease indications.

Clinical research Phase III Regulatory
MORE ON THIS TOPIC
Medical technology. Doctor holding health icon with dna, electronic medical record. Digital healthcare and research with global network connection on hologram virtual screen, insurance, digital health technology
Partnered
Ending the Diagnostic Odyssey for Patients
December 11, 2024
 · 
4 min read
 · 
BioSpace Insights
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac